Paclitaxel in relapsed high risk anthracycline treated breast cancer patients.
Elhabbash
Manal
M
Department of Oncology, Tripoli Medical Center, PO Box 83763, Tripoli, Libya. manalelhabbsh@yahoo.com
Alwindi
Abukris A
AA
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage*; D017697:Premenopause; D012074:Remission Induction; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis
D018943:Anthracyclines; D017239:Paclitaxel